Cerus Endovascular Strengthens Board of Directors with Appointment of John T. Kilcoyne
FREMONT, Calif. and OXFORD, England, Sept. 18, 2018
FREMONT, Calif. and OXFORD, England, Sept. 18, 2018 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems to treat acute, life-threatening intracranial aneurysm, today announced it has appointed John Kilcoyne to its board of directors, effective immediately.
Mr. Kilcoyne brings more than 30 years of experience in the medical device market to the Cerus Endovascular Board. Most recently, Mr. Kilcoyne was chief executive officer of ReVision Optics. Prior to ReVision Optics, he served as chief executive officer and chairman of Micrus Endovascular, which he took public and then successfully led for six years until its sale to Johnson & Johnson in 2010. From 2002 to 2004, he served as president and chief executive officer of medical device company Solace Therapeutics. Prior to Solace, he served as the president and chief executive officer of Endonetics, Inc. until its acquisition by Medtronic in 2001. Mr. Kilcoyne received his B.S. from Cornell University.
"John has a proven track record of advancing companies from development to commercial-stage operations," said Sam J. Milstein, PhD, lead director of Cerus Endovascular. "In addition to strategy and commercialization skills, John brings to Cerus a deep understanding of the needs of patients as well as doctors in the treatment of vascular disease and neurological conditions, and we look forward to benefitting from his counsel."
Mr. Kilcoyne stated, "This is an exciting time to join the Cerus Endovascular Board as the company is keenly focused on developing compelling therapeutic devices for the treatment of hemorrhagic stroke – in particular its novel aneurysm treatments, which address a significant unmet clinical need. I look forward to providing my support as the Cerus team works diligently to improve patient outcomes and drive shareholder value."
About Cerus Endovascular
Founded in 2013, Cerus Endovascular is a privately held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysm. The company's first product, the Contour Neurovascular System™, is a pre-shaped structure of fine mesh braid with shape memory properties that is delivered to the aneurysm via an endovascular micro-catheter. The company is also developing a pipeline of complementary devices, leveraging the design concept of the Contour Neurovascular System™ to address the full range of size, type and location of cerebral aneurysms with which a patient can present to the clinician.
Melody A. Carey
Rx Communications Group, LLC
SOURCE Cerus Endovascular Ltd.